Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Tao Sun(Shandong Provincial Hospital), Hu Liu(Nanjing Medical University), Xinhong Wu(Hubei Cancer Hospital), Ting Luo(ZheJiang Academy of Agricultural Sciences), Ying Cheng(Jilin Province Tumor Hospital), Jing Cheng(Wuhan Puai Hospital), Xiaojia Wang(Henan University of Science and Technology), Xiaohua Zeng(Chongqing Cancer Hospital), Yuee Teng(First Hospital of China Medical University), Min Yan(Shanxi Agricultural University), Changsheng Ye(Nanfang Hospital), Zhongsheng Tong(Institute of Oncology NN Petrov), Wěi Li(Shougang (China)), Qiang Liu(Sun Yat-sen University), Cuizhi Geng(Hebei Medical University), Huiping Li(Peking University), Shusen Wang(Sun Yat-sen University), Jincai Zhong(Guangxi Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Xiaoyu Zhu(Jiangsu Hengrui Medicine (China)), Xinshuai Wang(Henan University of Science and Technology), Jianyun Nie(Kunming Medical University), Quchang Ouyang(Hunan Cancer Hospital), Shu-chao Wu(Jiangsu Hengrui Medicine (China)), Jin Yang(First Affiliated Hospital of Xi'an Jiaotong University), Yongsheng Wang(Lanzhou University of Technology), Fangli Dong(Jiangsu Hengrui Medicine (China)), Qinguo Mo(Tumor Hospital of Guangxi Medical University)
Cited by 82
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k